CN106377793A - Compound liquid dressing and preparation method thereof - Google Patents
Compound liquid dressing and preparation method thereof Download PDFInfo
- Publication number
- CN106377793A CN106377793A CN201611008271.7A CN201611008271A CN106377793A CN 106377793 A CN106377793 A CN 106377793A CN 201611008271 A CN201611008271 A CN 201611008271A CN 106377793 A CN106377793 A CN 106377793A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound liquid
- liquid dressing
- percutaneous absorption
- absorption enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medical biological polymer materials, and provides a compound liquid dressing and a preparation method thereof. The compound liquid dressing is prepared from the following ingredients in parts by weight: 0.1 to 5 parts of itching relieving agents, 1 to 5 parts of pain relieving agents, 0.1 to 1 part of antibacterial agents, 3 to 6 parts of anti-inflammatory agents, 5 to 10 parts of skin penetration enhancers, 5 to 30 parts of moisture preserving agents and 43 to 85.8 parts of water and/or alcohol solvents. The compound liquid dressing has the efficacies of stopping bleeding, inhibiting bacteria, relieving pain and inflammation, relieving itching and preserving moisture, and has the characteristics of good water solubility, film-forming property, antibacterial property, wound healing promotion, biocompatibility, biodegradability and the like; contained functional components can easily realize transdermal absorption, so that the wound healing is accelerated.
Description
Technical field
The invention belongs to medical bio polymeric material field is and in particular to a kind of compound liquid dressing and its preparation side
Method.
Background technology
Dressing may be defined as substituting damaged skin temporarily, and the tissue making below epidermis is from extraneous various unfavorable factors
Invasion.Common human body skin is impaired burn and scald, acute and chronic ulcer, mechanical scuffing, surgical wound etc..The mankind use dressing
Carry out nursing existing history of more than one thousand years to wound, and the lifting with scientific and technical development and human knowledge's level and constantly send out
Give birth to and change.Proposing and being confirmed with " wound wet union is theoretical ", various new pattern compress arise at the historic moment.Apply from new
From the point of view of the clinical practice of material, new pattern compress dryness traditional dressing as compared with the past, the progress of its nursing level is obvious.
Because modern's life style has a very large change, the wound type easily occurring has substantially as compared with the past
Difference, wound type is more complicated, and patient can select the safest, warp according to own wound situation and ability to shoulder economically
Ji, effective dressing.Based on the consideration of these factors, researcher has done substantial amounts of work, mainly adopts composite technology
The range of application to widen dressing for the method.However, the existing dressing using this technological development also difficult to reach preferably will
Ask；For common minor cut or wound, lack a kind of care method of simple efficient and cost-effective.
Liquid dressing is a kind of non-closed Lipido-colloid dressing not gluing wound, and glue microgranule and whole liquid dressing become
Point be not dispersed in viscous wound has on the polyester webs of vaseline oil covering or is sprayed directly on wound surface, is that the healing of wound carries
For a moist microenvironment.In recent years, with the progress of technology, liquid dressing has also obtained quick development, presents many
The development trend of sample.However, due to liquid dressing, often function is more single, and general Percutaneous absorption enhancer can not
The feature of the rheological characteristic according to different liquids dressing and caking property is adjusted, and leads to functional component can not carry out in skin surface
Fully absorb, therefore in terms of promoting wound healing, effect is not fairly obvious.
Content of the invention
It is an object of the invention to solving defect of the prior art, there is provided a kind of compound liquid dressing and its preparation
Method, this compound liquid dressing has functions that hemostatic bacteriostatic, anti-inflammatory analgetic, antipruritic moisturizing, and good water solublity, one-tenth
The characteristics such as film, antibiotic property, wound healing, biocompatibility and biodegradability, and the functional component containing is easy
Realize Transdermal absorption, thus accelerating the healing of wound.
For achieving the above object, the technical scheme is that：A kind of compound liquid dressing, by prurituss, analgesic,
Antibacterial, antiinflammatory, Percutaneous absorption enhancer, wetting agent, water and/or alcoholic solvent are constituted, and each constituent is counted by weight：
0.1 ~ 5 part of prurituss, 1 ~ 5 part of analgesic, 0.1 ~ 1 part of antibacterial, 3 ~ 6 parts of antiinflammatory, 5 ~ 10 parts of Percutaneous absorption enhancer, moisturizing
5 ~ 30 parts of agent, water and/or 43 ~ 85.8 parts of alcoholic solvent.
Preferably, described prurituss are IPBC, dihydro Herba bromi japonici acyl group o-amino benzoyl
One or more of sour D, aloe-emodin, isethionic acid own oxygen benzamidine mixes.
Preferably, described analgesic is that one or more of Radix Saposhnikoviae, diclofenac, acetaminophen mix.
Preferably, described antibacterial be shitosan, tannin, Zinc Pyrithione, vanillin, in polyhexamethylene guanidine one
Plant or several mixing.
Preferably, described antiinflammatory is that one or more of Ciprofloxacin, allantoin, metronidazole mix.
Preferably, described Percutaneous absorption enhancer is amide modifications castor oil hydrogenated and azone by weight 1：3 ~ 4
Mixture.
Preferably, described wetting agent is that one or more of Oligomeric maltose, glycerol, carboxymethyl cellulose mix.
Preferably, described alcoholic solvent is that one or more of Polyethylene Glycol, 1,2-PD, butanediol mix.
For preparing above-mentioned compound liquid dressing, the present invention also provides the preparation method of this compound liquid dressing：
1）Weigh prurituss, antiinflammatory and antibacterial by formula ratio, be added in the water of 1/3 formula ratio and/or alcoholic solvent and stir
To being completely dissolved, form liquid A, indwelling；
2）Weigh wetting agent and analgesic by formula ratio, be added in the water of 1/3 formula ratio and/or alcoholic solvent and stir to completely molten
Solution, forms liquid B, indwelling；
3）Weigh Percutaneous absorption enhancer by formula ratio, pour in liquid A successively with liquid B and mix homogeneously, form liquid C, plus
Enter water and/or the alcoholic solvent of 1/3 formula ratio, be stirred well to mix homogeneously, fill, obtain compound liquid dressing.
Further, the preparation process of described Percutaneous absorption enhancer is specially：By etc. the Colophonium of quality and deionization
Water mixes, and dissolves at 100 ~ 150 DEG C, adds castor oil hydrogenated vacuum stirring 30 ~ 60min, is down to room temperature and obtains final product amide and changes
Property castor oil hydrogenated；By weight for 1：3 ~ 4 take amide modifications castor oil hydrogenated and azone respectively, are sufficiently stirred for, mix homogeneously,
Percutaneous absorption enhancer i.e..
Due to having multi-efficiency, its implementation depends on Transdermal absorption to the compound liquid dressing that the present invention is formed
Accelerator has epidermal absorption to functional component.Percutaneous absorption enhancer promote Transdermal absorption mechanism be：In the technology of the present invention bar
The amide modifications castor oil hydrogenated carrying out under part becomes a kind of thixotropic agent, can adjust the rheological property of thick liquid dressing；And nitrogen
Ketone can keratodermatitis are planocellular to fold structure set in order by changing（It is allowed to ordered arrangement and be changed into disorderly arranged）, increase angle
The space in matter confluent monolayer cells gap, can make the thick liquid dressing functional component of adjusted rheological property quickly enter Intradermal and inhale
Receive, thus being easier to play effect of each functional component in wound surface.
Compared with prior art, the technical scheme that the present invention provides has the advantages that：
1）The present invention passes through the compounding of various ingredients and suitable additives, obtains several and had both had hemostatic bacteriostatic, anti-inflammatory analgetic, only
Itch effect of moisturizing, have good water solublity, film property, antibiotic property, wound healing, biocompatibility and biology can again
The compound liquid dressing of the characteristics such as degradability, coatable in organism wound, the such as position such as staff, extremity, abdominal part, rise
To isolation, protective effect.
2）So that the functional component such as tannin, Oligomeric maltose easily realizes transdermal in the presence of Percutaneous absorption enhancer
Absorb, enhance immunity and the anti-virus ability of body, these functional component materials are being realized answering without digestive tract simultaneously
Some functions, alleviate its burden to human viscera organ.
3）The compound liquid dressing that the present invention provides achieves antipruritic function, the allergy such as mosquito bite for skin
During property wound, there is good effect.
4）The compound liquid dressing that the present invention provides has the several functions such as hemostatic bacteriostatic, anti-inflammatory analgetic simultaneously, widens
The range of application to wound care for this liquid dressing, hence it is evident that contracting under the complex role of wetting agent and Percutaneous absorption enhancer
The healing time of short wound.
5）The compound liquid dressing that the present invention provides is sprayed at skin surface, solidifies quickly after adhesion, forms molecular level
Stealthy antibacterial film, outer layer is cationic layer, and film is firmly connected in chemical bond mode by the macromolecule organic silicon with skin surface.Sun
Sheath has strong adsorption to act on to pathogenic microorganisms such as negatively charged antibacterial, funguses, viruses, so that pathogenic microorganism is rely
Existence respiratory enzyme is ineffective and death by suffocation.Therefore there is long-acting broad-spectrum antibacterial, reduce and form cicatrix, and to wound healing
There is good therapeutic effect.
6）The compound liquid dressing product biological safety that the present invention provides is high, moderate, can flexibly be coated on body
The grieved affected part at each position of body, extremely easy to use, thus the very strong market competitiveness.
Specific embodiment
With reference to embodiment, technical scheme is described further.
Embodiment 1
A kind of compound liquid dressing, by prurituss, analgesic, antibacterial, antiinflammatory, Percutaneous absorption enhancer, wetting agent, water
And/or alcoholic solvent is constituted, each constituent is counted by weight：
0.1 part of IPBC
5 parts of diclofenac
0.5 part of tannin
0.5 part of Zinc Pyrithione
3 parts of Ciprofloxacin
8 parts of Percutaneous absorption enhancer
20 parts of Oligomeric maltose
41.9 parts of Polyethylene Glycol
21 parts of 1,2- propylene glycol.
The preparation process of described Percutaneous absorption enhancer is specially：By etc. the Colophonium of quality and deionized water mixing, and
Dissolve at 150 DEG C, add castor oil hydrogenated vacuum stirring 30min, be down to room temperature and obtain final product amide modifications castor oil hydrogenated；By weight
Than for 1：3 take amide modifications castor oil hydrogenated and azone respectively, are sufficiently stirred for, mix homogeneously, Percutaneous absorption enhancer that is,.
Embodiment 2
A kind of compound liquid dressing, by prurituss, analgesic, antibacterial, antiinflammatory, Percutaneous absorption enhancer, wetting agent, water
And/or alcoholic solvent is constituted, each constituent is counted by weight：
2 parts of dihydro Herba bromi japonici acyl group ortho-aminobenzoic acid D
1 part of Radix Saposhnikoviae
0.5 part of shitosan
5 parts of allantoin
5 parts of Percutaneous absorption enhancer
30 parts of glycerol
42.4 parts of Polyethylene Glycol
14.1 parts of butanediol.
The preparation process of described Percutaneous absorption enhancer is specially：By etc. the Colophonium of quality and deionized water mixing, and
Dissolve at 100 DEG C, add castor oil hydrogenated vacuum stirring 60min, be down to room temperature and obtain final product amide modifications castor oil hydrogenated；By weight
Than for 1：4 take amide modifications castor oil hydrogenated and azone respectively, are sufficiently stirred for, mix homogeneously, Percutaneous absorption enhancer that is,.
Embodiment 3
A kind of compound liquid dressing, by prurituss, analgesic, antibacterial, antiinflammatory, Percutaneous absorption enhancer, wetting agent, water
And/or alcoholic solvent is constituted, each constituent is counted by weight：
5 parts of isethionic acid own oxygen benzamidine
3 parts of acetaminophen
0.025 part of vanillin
0.075 part of shitosan
4 parts of metronidazole
10 parts of Percutaneous absorption enhancer
30 parts of carboxymethyl cellulose
35.9 parts of Polyethylene Glycol
12 parts of deionized water.
The preparation process of described Percutaneous absorption enhancer is specially：By etc. the Colophonium of quality and deionized water mixing, and
Dissolve at 120 DEG C, add castor oil hydrogenated vacuum stirring 45min, be down to room temperature and obtain final product amide modifications castor oil hydrogenated；By weight
Than for 1：3.5 take amide modifications castor oil hydrogenated and azone respectively, are sufficiently stirred for, mix homogeneously, Percutaneous absorption enhancer that is,.
Embodiment 4
A kind of compound liquid dressing, by prurituss, analgesic, antibacterial, antiinflammatory, Percutaneous absorption enhancer, wetting agent, water
And/or alcoholic solvent is constituted, each constituent is counted by weight：
3.6 parts of aloe-emodin
1.4 parts of isethionic acid own oxygen benzamidine
3.3 parts of Radix Saposhnikoviae
1.7 parts of diclofenac
1 part of polyhexamethylene guanidine
1.5 parts of Ciprofloxacin
4.5 parts of allantoin
10 parts of Percutaneous absorption enhancer
4.3 parts of Oligomeric maltose
0.7 part of glycerol
68 parts of Polyethylene Glycol.
The preparation process of described Percutaneous absorption enhancer is specially：By etc. the Colophonium of quality and deionized water mixing, and
Dissolve at 140 DEG C, add castor oil hydrogenated vacuum stirring 40min, be down to room temperature and obtain final product amide modifications castor oil hydrogenated；By weight
Than for 1：4 take amide modifications castor oil hydrogenated and azone respectively, are sufficiently stirred for, mix homogeneously, Percutaneous absorption enhancer that is,.
Embodiment 5
A kind of compound liquid dressing of the arbitrary example of embodiment 1～embodiment 4, the comprising the following steps that of its preparation method：
1）Weigh prurituss, antiinflammatory and antibacterial by formula ratio, be added in the water of 1/3 formula ratio and/or alcoholic solvent and stir
To being completely dissolved, form liquid A, indwelling；
2）Weigh wetting agent and analgesic by formula ratio, be added in the water of 1/3 formula ratio and/or alcoholic solvent and stir to completely molten
Solution, forms liquid B, indwelling；
3）Weigh Percutaneous absorption enhancer by formula ratio, pour in liquid A successively with liquid B and mix homogeneously, form liquid C, plus
Enter remaining water and/or alcoholic solvent, be stirred well to mix homogeneously, fill, obtain compound liquid dressing.
Embodiment 6 antibacterial experiment
Anti-microbial Performance Tests：Evaluation third portion according to GB/T 20944.3-2008 antibacterial textile performance：Shake flask test, surveys
Determine the anti-microbial property of product of the present invention.Strain used is Candida albicans, escherichia coli and staphylococcus aureuses, bacterial concentration
For 105~107cfu/mL.Buffer saline and casting product is added first in triangular flask, high in 0.1MPa steam and 121 DEG C
Warming middle-JIAO sterilizing 20min, is cooled to room temperature, pipettes 1mL bacterium solution with the aseptic measuring pipette of 1mL, add in above-mentioned triangular flask.For making examination
Sample contacts by force with antibacterial, vibrates a few hours in 37 DEG C of shaking tables.After taking vibration front and vibrating, solution 0.1mL is applied to Nutrient agar training
On foster base, compare after 37 DEG C, 24h constant temperature culture, its result is as shown in table 1.
Table 1 bacteriostatic experiment result
| Bacteriostasis rate | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 |
| Escherichia coli | >99.9 | >95 | >96 | >95 |
| Staphylococcus aureuses | >95 | >99.9 | >99.9 | >99.9 |
| Candida albicans | >99.9 | >95 | >99.9 | >99.9 |
By the result of bacteriostatic test it will be seen that the casting product of the present invention is to Gram-positive and negative bacterium and funguses etc.
It is respectively provided with good effect, more than 95% is reached to the bacteriostasis rate of all kinds of antibacterials and funguses, therefore this compound liquid dressing can be effective
Prevent wound from being infected.
Embodiment 7 Transdermal Absorption is tested
Take at male SD rat after death, shave off rat abdomen Mus hair with electric shaver-for women, take skin of abdomen, with normal saline repeatedly
Rinse well, be placed on glass plate, carefully peel off subcutaneous layer of fat, carry out penetrating absorption immediately.Double using improving Franz
Room diffusion device (diffusion area 1.77cm2, spread pool volume 7mL).The isolated rat handled well skin is placed in level
Diffusion cell junction, stratum corneum side is towards supply pool, and is fixed with alligator clamp.Excessive the present embodiment 1 ~ 4 institute is added in supply pool
The liquid dressing being formed（Using normal saline as blank solution）, in acceptance pool, add normal saline, constant speed electromagnetic agitation (300r
min-1), diffusion cell interlayer bath temperature is maintained at (32 ± 0.2) DEG C.Respectively predetermined time (1,2,3,4,6,8,10,12,
14,16,24h) sample 1mL from acceptance pool, and supplement the normal saline of equivalent immediately, sample liquid filters through 0.45 μm of microporous filter membrane
Cross, carry out assay, calculate its Steady penetration rate（Jss）, its result is as shown in table 2.
The related Transdermal absorption parameter (n=3, x ± s) of table 2
| Group | Jss/μg·cm-2·h |
| Blank | 3.24±1.15 |
| Embodiment 1 | 12.64±4.08 |
| Embodiment 1 | 11.21±3.72 |
| Embodiment 1 | 14.58±4.50 |
| Embodiment 4 | 13.89±3.58 |
The liquid dressing product of the present invention is can be seen that from above table, because it contains special Percutaneous absorption enhancer,
Its percutaneous absorption rate can be made to be obviously improved.
Embodiment 8 haemostatic effect evaluation（New zealand rabbit arterial hemorrhage animal model）
Choose body weight 3.0 ~ 5.0kg new zealand rabbit and be divided into five groups, every group 6, contrast four embodiment products of the present invention and blank
Sample（It is not added with any hemostatic material）Haemostatic effect.During experiment, slowly inject pentobarbital sodium by 40mg/kg dose intravenous molten
After liquid anesthetized animal, its central arteria auricularises region preserved skin, sterilization cut skin along arteria auricularises direction, blunt separation goes out ear and moves
Arteries and veins, vein and nerve, then with scalpel transversely cutting tremulous pulse, after blood is gushed out, it is pasted on wound with 1 layer of test material immediately
Surface the pressure using pull and push dynamometer applying 3N, record bleeding stopping period and blood loss, result is as shown in table 3.
Table 3 product haemostatic effect
| Group | Clotting time (s) |
| Blank control group | Can not stop blooding |
| The embodiment of the present invention 1 | 128±37 |
| The embodiment of the present invention 2 | 119±28 |
| The embodiment of the present invention 3 | 136±31 |
| The embodiment of the present invention 4 | 130±22 |
From upper table experiment results proved, the composite fluid dressing of present invention preparation, for Blood clotting, can speculate and reach for wound
Effect to quick-acting haemostatic powder.
Embodiment 9 animal wound healing assay
Take Male New Zealand rabbits, 72, every 2 ~ 3kg, it is randomly divided into six groups, every group 12.Each rabbit is all according to clinical animal
Experimental burning master pattern preparation method all causes 30%TBSA shallow II degree to burn, and wherein A group rabbit does not use any dressing, B group
Rabbit application cotton balls containing povidone iodine, the composite fluid dressing of C, D, E, F group application embodiment of the present invention 1 ~ 4, change twice daily, directly
Wound healing to C, D, E, F group just terminates this zoopery.
From zooperal result, after the respective dressing of C ~ F group rabbit wound surface application, wound surface all no infection phenomenons,
No red and swollen generation.And from healing time, the healing time of C ~ F group rabbit wound surface is considerably less than B group, time difference has aobvious
Write meaning, be shown in Table 4：
Table 4 each group animal traumatic infection and healing state (%)
| Group | Wound infection rate (%) | 7d healing rate (%) | Healing time (d) |
| A group | 100 | Red and swollen | After 15d, redness is gradually moved back, and starts to form a scab |
| B group | 0 | Slightly red and swollen | 18.2±2.4 |
| C group | 0 | 73.6±2.5 | 9.7±1.5 |
| D group | 0 | 71.8±1.4 | 10.6±1.6 |
| E group | 0 | 69.9±2.0 | 11.8±1.9 |
| F group | 0 | 72.5±1.8 | 10.9±2.1 |
From the whole result of six groups of experiments, the dressing of povidone iodine cotton balls dressing and present invention preparation can play to the healing of wound surface
The effect accelerating, and C ~ F group dressing is because of containing functional components such as antibacterial, antiinflammatory and cutaneous permeable agents, in the presence of wetting agent
Effectively nuring wound, significantly improves the microenvironment of wound surface local, wound healing simultaneously shortens healing time.
Obviously, the above embodiment of the present invention is only intended to clearly illustrate example of the present invention, and is not right
The restriction of embodiments of the present invention；For those of ordinary skill in the field, also may be used on the basis of the above description
To make other changes in different forms, there is no need to be exhaustive to all of embodiment；All this
Any modification, equivalent and improvement made within the spirit of invention and principle etc., should be included in the claims in the present invention
Protection domain within.
Claims (10)
1. a kind of compound liquid dressing is it is characterised in that described compound liquid dressing is by prurituss, analgesic, antibacterial
Agent, antiinflammatory, Percutaneous absorption enhancer, wetting agent, water and/or alcoholic solvent are constituted, and each constituent is counted by weight：Antipruritic
0.1 ~ 5 part of agent, 1 ~ 5 part of analgesic, 0.1 ~ 1 part of antibacterial, 3 ~ 6 parts of antiinflammatory, 5 ~ 10 parts of Percutaneous absorption enhancer, wetting agent 5 ~
30 parts, water and/or 43 ~ 85.8 parts of alcoholic solvent.
2. a kind of compound liquid dressing according to claim 1 is it is characterised in that described prurituss are iodopropynyl
In base butyl carbamate, dihydro Herba bromi japonici acyl group ortho-aminobenzoic acid D, aloe-emodin, isethionic acid own oxygen benzamidine one
Plant or several mixing.
3. a kind of compound liquid dressing according to claim 1 it is characterised in that described analgesic be Radix Saposhnikoviae, double
One or more of the fragrant acid of chlorine, acetaminophen mixing.
4. a kind of compound liquid dressing according to claim 1 it is characterised in that described antibacterial be shitosan,
One or more of tannin, Zinc Pyrithione, vanillin, polyhexamethylene guanidine mix.
5. a kind of compound liquid dressing according to claim 1 is it is characterised in that described antiinflammatory is that ring third is husky
One or more of star, allantoin, metronidazole mix.
6. a kind of compound liquid dressing according to claim 1 is it is characterised in that described Percutaneous absorption enhancer is
Amide modifications castor oil hydrogenated and azone by weight 1：3 ~ 4 mixture.
7. a kind of compound liquid dressing according to claim 1 is it is characterised in that described wetting agent is oligosaccharide malt
One or more of sugar, glycerol, carboxymethyl cellulose mix.
8. a kind of compound liquid dressing according to claim 1 is it is characterised in that described alcoholic solvent is poly- second two
One or more of alcohol, 1,2- propylene glycol, butanediol mix.
9. the preparation method of a kind of compound liquid dressing according to any one of claim 1 ~ 8 is it is characterised in that described
The comprising the following steps that of preparation method：
1）Weigh prurituss, antiinflammatory and antibacterial by formula ratio, be added in the water of 1/3 formula ratio and/or alcoholic solvent and stir
To being completely dissolved, form liquid A, indwelling；
2）Weigh wetting agent and analgesic by formula ratio, be added in the water of 1/3 formula ratio and/or alcoholic solvent and stir to completely molten
Solution, forms liquid B, indwelling；
3）Weigh Percutaneous absorption enhancer by formula ratio, pour in liquid A successively with liquid B and mix homogeneously, form liquid C, plus
Enter water and/or the alcoholic solvent of 1/3 formula ratio, be stirred well to mix homogeneously, fill, obtain compound liquid dressing.
10. a kind of preparation method of compound liquid dressing according to claim 9 is it is characterised in that described transdermal is inhaled
The preparation process receiving accelerator is specially：By etc. the Colophonium of quality and deionized water mixing, and dissolve at 100 ~ 150 DEG C, plus
Enter castor oil hydrogenated vacuum stirring 30 ~ 60min, be down to room temperature and obtain final product amide modifications castor oil hydrogenated；By weight for 1：3 ~ 4 points
Do not take amide modifications castor oil hydrogenated and azone, be sufficiently stirred for, mix homogeneously, Percutaneous absorption enhancer that is,.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611008271.7A CN106377793A (en) | 2016-11-16 | 2016-11-16 | Compound liquid dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611008271.7A CN106377793A (en) | 2016-11-16 | 2016-11-16 | Compound liquid dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106377793A true CN106377793A (en) | 2017-02-08 |
Family
ID=57958919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611008271.7A Pending CN106377793A (en) | 2016-11-16 | 2016-11-16 | Compound liquid dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106377793A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109224124A (en) * | 2018-11-21 | 2019-01-18 | 广州润虹医药科技股份有限公司 | A kind of liquid dressing of functions of stanching and promoting healing |
| CN109289084A (en) * | 2018-10-30 | 2019-02-01 | 河南汇博医疗股份有限公司 | A kind of surface of a wound antibacterial liquid dressing and preparation method thereof |
| CN109364290A (en) * | 2018-11-12 | 2019-02-22 | 新疆维吾尔自治区分析测试研究院 | A kind of Lavender liposome liquid adhesive bandage and preparation method thereof |
| CN110624127A (en) * | 2019-10-14 | 2019-12-31 | 河南承东生物科技有限公司 | Dual-bacteriostatic healing-promoting liquid dressing and preparation method thereof |
| CN110742820A (en) * | 2019-11-29 | 2020-02-04 | 福州百草堂医药科技有限公司 | Dihydroartemisine D-salt cosmetic agents and uses thereof |
| CN110772660A (en) * | 2019-12-14 | 2020-02-11 | 广东泰宝医疗科技股份有限公司 | Preparation method of guanidinated chitosan dressing |
| CN111358749A (en) * | 2020-05-09 | 2020-07-03 | 山东兴瑞生物科技有限公司 | Composition for promoting skin wound healing and preparation method thereof |
| CN112516379A (en) * | 2020-10-26 | 2021-03-19 | 上海迪派生物科技有限公司 | Liquid wound dressing with sustained antimicrobial capability |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920158A (en) * | 1989-10-11 | 1990-04-24 | Medipro Sciences Limited | Hydrogel-forming wound dressing or skin coating material |
| CN1222849A (en) * | 1996-04-30 | 1999-07-14 | 海德罗默公司 | Composition, barrier film and method for preventing contact dermatitis |
| CN101494976A (en) * | 2005-12-14 | 2009-07-29 | 扎尔斯制药公司 | Compositions and methods for dermally treating pain |
| CN102228715A (en) * | 2011-06-10 | 2011-11-02 | 青岛明药堂医药科技开发有限公司 | Liquid dressing containing chitosan derivative and preparation method thereof |
| CN104307032A (en) * | 2014-11-05 | 2015-01-28 | 天津工业大学 | Liquid dressing capable of stopping pain and bleeding, resisting bacteria and promoting wound healing |
| CN105079858A (en) * | 2015-08-10 | 2015-11-25 | 贵州扬生医用器材有限公司 | Liquid dressing capable of sterilizing and repairing wounds and production method of liquid dressing |
-
2016
- 2016-11-16 CN CN201611008271.7A patent/CN106377793A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920158A (en) * | 1989-10-11 | 1990-04-24 | Medipro Sciences Limited | Hydrogel-forming wound dressing or skin coating material |
| CN1222849A (en) * | 1996-04-30 | 1999-07-14 | 海德罗默公司 | Composition, barrier film and method for preventing contact dermatitis |
| CN101494976A (en) * | 2005-12-14 | 2009-07-29 | 扎尔斯制药公司 | Compositions and methods for dermally treating pain |
| CN102228715A (en) * | 2011-06-10 | 2011-11-02 | 青岛明药堂医药科技开发有限公司 | Liquid dressing containing chitosan derivative and preparation method thereof |
| CN104307032A (en) * | 2014-11-05 | 2015-01-28 | 天津工业大学 | Liquid dressing capable of stopping pain and bleeding, resisting bacteria and promoting wound healing |
| CN105079858A (en) * | 2015-08-10 | 2015-11-25 | 贵州扬生医用器材有限公司 | Liquid dressing capable of sterilizing and repairing wounds and production method of liquid dressing |
Non-Patent Citations (2)
| Title |
|---|
| 涂料工艺编委会编: "《涂料工艺（下册）》", 31 December 1997 * |
| 石军等编: "《热熔胶黏剂实用手册-松香》", 31 May 2004 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109289084A (en) * | 2018-10-30 | 2019-02-01 | 河南汇博医疗股份有限公司 | A kind of surface of a wound antibacterial liquid dressing and preparation method thereof |
| CN109364290A (en) * | 2018-11-12 | 2019-02-22 | 新疆维吾尔自治区分析测试研究院 | A kind of Lavender liposome liquid adhesive bandage and preparation method thereof |
| CN109224124A (en) * | 2018-11-21 | 2019-01-18 | 广州润虹医药科技股份有限公司 | A kind of liquid dressing of functions of stanching and promoting healing |
| CN110624127A (en) * | 2019-10-14 | 2019-12-31 | 河南承东生物科技有限公司 | Dual-bacteriostatic healing-promoting liquid dressing and preparation method thereof |
| CN110742820A (en) * | 2019-11-29 | 2020-02-04 | 福州百草堂医药科技有限公司 | Dihydroartemisine D-salt cosmetic agents and uses thereof |
| CN110772660A (en) * | 2019-12-14 | 2020-02-11 | 广东泰宝医疗科技股份有限公司 | Preparation method of guanidinated chitosan dressing |
| CN111358749A (en) * | 2020-05-09 | 2020-07-03 | 山东兴瑞生物科技有限公司 | Composition for promoting skin wound healing and preparation method thereof |
| CN112516379A (en) * | 2020-10-26 | 2021-03-19 | 上海迪派生物科技有限公司 | Liquid wound dressing with sustained antimicrobial capability |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106377793A (en) | Compound liquid dressing and preparation method thereof | |
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| KR890001881B1 (en) | Composition of cream base | |
| US20020090401A1 (en) | Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia | |
| CN102302458B (en) | Long-acting sustained-release wound dressing containing levofloxacin sustained-release microspheres, and preparation method thereof | |
| US20080020025A1 (en) | Composition for wound care and method of using same | |
| CN109646712B (en) | Colloidal sulfur liquid dressing and preparation method thereof | |
| US8252335B2 (en) | Healing powder and method of use thereof | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| CN106063798B (en) | Oral ulcer treatment patch film and preparation method thereof | |
| CN102657602A (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
| JPH04288017A (en) | Treating agent for pimple | |
| DE69723725T2 (en) | METHOD FOR PRODUCING CONCENTRATED SOLUTIONS OF FIBRONECTIN WITHOUT BUFFER | |
| CN107595819B (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
| RU2336877C1 (en) | Local antimicrobial agent | |
| CN110198731B (en) | Antimicrobial composition comprising sodium dimercaptopropane sulfonate and dimethyl sulfoxide, use of the composition, and wound treatment methods using the same | |
| CN114272261A (en) | A topical skin preparation containing povidone iodine for treating psoriasis | |
| WO2022126628A1 (en) | Liquid adhesive bandage and preparation method therefor | |
| KR102096257B1 (en) | Preservative compositions and uses of compositions comprising polyvinylpyrrolidone and unityol | |
| RU2447082C1 (en) | Method of stimulating skin and mucous lining defect repair and medicinal agent for realising said method | |
| RU2647458C1 (en) | Wound-healing, anti-inflammatory ointment on the basis of tea fungus (medusomyces gisevii lindau) | |
| CN112263544A (en) | Lidocaine hydrochloride gel and preparation method thereof | |
| WO2007143586A2 (en) | Composition for wound care and method of using same | |
| CN113143844B (en) | Polymer microneedle patch for treating acne and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170208 |